Infliximab in patients who have spondyloarthropathy: Clinical efficacy, safety, and biological immunomodulation

Rheumatic Disease Clinics of North America

Volumn 29, Issue 3, 2003, Pages 463-479

  De Keyser, Filip ^a   Baeten, Dominique ^a   Van den Bosch, Filip ^a   Kruithof, Elli ^a   Mielants, Herman ^a   Veys, Eric M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DNA ANTIBODY; DOUBLE STRANDED DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; GAMMA INTERFERON; HISTONE ANTIBODY; INDOMETACIN; INFLIXIMAB; INTERLEUKIN 2; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSOME ANTIBODY; PHENYLBUTAZONE; PIROXICAM; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANKYLOSING SPONDYLITIS; ARTHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENTERITIS; FEVER; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LIVER NODULE; LONG TERM CARE; LYMPHADENOPATHY; MALAISE; MEDIASTINUM LYMPH NODE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SPLEEN INJURY; SPONDYLOARTHROPATHY; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; TUBERCULOSIS;

EID: 0041520737     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00052-8     Document Type: Review

References (65)

1. Wright V. Seronegative polyarthritis. A unified concept. Arthritis Rheum 1978;21:619-33.
2. Granfors K, Marker-Hermann E, De Keyser F, Khan MA, Veys EM, Yu DT. The cutting edge of spondylarthropathy research in the millennium. Arthritis Rheum 2002;46:606-13.
3. Dougados M, Van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondyloarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
4. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9.
5. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
6. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
7. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
8. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
9. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
10. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
11. De Keyser F, Elewaut D, De Vos M, De Vlam K, Cuvelier C, Mielants H, et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin N Am 1998;24:785-813.
12. Mielants H, Veys EM, Cuvelier C, De Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheum 1988;27(Suppl 2):95-105.
13. Simenon G, Van Gossum A, Adler M, Rickaert F, Appelboom T. Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 1990;17:1491-4.
14. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppala K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994;37:23-31.
15. Altomonte L, Zoli A, Veneziani A, Mirone L, Santacesaria G, Chiarelli C, et al. Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies. Clin Rheumatol 1994;13:565-70.
16. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al. The evolution of spondylarthropathies in relation to gut histology. Part I: clinical aspects. J Rheumatol 1995;22:2266-72.
17. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110:1696-703.
18. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al. The evolution of spondylarthropathies in relation to gut histology. Part III: relation between gut and joint. J Rheumatol 1995;22:2279-84.
19. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988;83:703-9.
20. Demetter P, De Vos M, Van Damme N, Baeten D, Elewaut D, Vermeulen S, et al. Focal upregulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated lineage. Am J Clin Pathol 2000;114:364-70.
21. Demetter P, Baeten D, De Keyser F, De Vos M, Van Damme N, Verbruggen G, et al. Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis 2000;59:211-6.
22. Van Damme N, Elewaut D, Baeten D, Demetter P, Cuvelier C, Verbruggen G, et al. Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. Clin Exp Rheumatol 2001;19:681-7.
23. Elewaut D, De Keyser F, Cuvelier C, Lazarovits AI, Mielants H, Verbruggen G, et al. Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1998;33:743-8.
24. Van Damme N, De Keyser F, Demetter P, Baeten D, Mielants H, Verbruggen G, et al. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol 2001;125:383-90.
25. Van Damme N, De Vos M, Baeten D, Demetter P, Mielants H, Verbruggen G, et al. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis 2001;60:495-9.
26. Hoffman I, Demetter P, Peeters M, De Vos M, Mielants H, Veys EM, et al. Anti-saccharomyces Cerevisiae antibodies are elevated in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003;62:455-9.
27. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on the articular symptoms. Lancet 2000;356:1821-2.
28. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
29. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-26.
30. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
31. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002;29:118-22.
32. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology [Oxford] 2002;41:1280-5.
33. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.
34. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
35. Muñoz-Villanueva MC, Collantes E, Gratacos J, Sanmarti R, Cañete JD, Zarco P, et al. Successful treatment of active and refractory spondyloarthritis with the anti-tumor necrosis factor A monoclonal antibody Infliximab. Ann Rheum Dis 2002;61(Suppl 1):300.
36. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12.
37. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 2002;22:227-32.
38. Wollina U, Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol 2002;16:127-9.
39. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587-9.
40. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002;46:886-91.
41. D'Agostino MA, Breban M, Said-Nahal R, Dougados M. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum 2002;46:840-1.
42. Kruithof E, Kestelyn P, Elewaut C, Elewaut D, Van den Bosch F, Mielants H, et al. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis 2002;61:470.
43. El-Shabrawi Y, Hermann J. Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al. Arthritis Rheum 2002;46:2821-2.
44. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
45. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
46. Braun J, Baraliakos X, Golder W, Listing J, Brandt J, Bollow M, et al. Improvement of spinal inflammation in ankylosing spondylitis by infliximab therapy as assessed by MRI using a novel evaluated spinal scoring system - results of a double-blind placebo-controlled trial. Arthritis Rheum 2002;46(Suppl):S426.
47. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNF alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-12.
48. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants F, Veys EM. Safety and efficacy of a retreatment regimen of 10 mg/kg Infliximab every 14 Weeks in patients with active spondylarthropathy. Arthritis Rheum 2002;46(Suppl):S430.
49. Brandt J, Listing J, Alten R, Burmester G, Gromnica-Ihle E, Schneider M, et al. One year results of a double-blind placebo controlled, Phase-III clinical trial of Infliximab in active ankylosing spondylitis. Arthritis Rheum 2002;46(Suppl):S429.
50. Baeten D, De Keyser F, Kruithof E, Van den Bosch F, Mielants H, Veys EM, et al. A systematic review of the serious and atypical infections in spondyloarthropathy patients treated with anti-TNF alpha: a clue to immune alterations of the innate immune system? Arthritis Rheum 2002;46(Suppl):S432.
51. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
52. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum 2000;43:2383-90.
53. De Rycke L, Kruithof E, Van Damme N, Hoffman I, Van den Bosch F, Veys E, et al. Antinuclear antibody profile following infliximab treatment in rheumatoid arthritis and spondyloarthropathy. Arthritis Rheum 2003;48:1015-23.
54. Baeten D, De Keyser F, Van Damme N, Veys EM, Mielants H. Influence of the gut and cytokine patterns in spondyloarthropathy. Clin Exp Rheumatol 2002;20(Suppl 28):S38-42.
55. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544-52.
56. Yin Z, Braun J, Neure L, Wu P, Liu L, Eggens U, et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum 1997;40:1788-97.
57. Baeten D, Van Damme N, Van den Bosch F, Kruithof E, De Vos M, Mielants H, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001;60:750-5.
58. Zou JX, Braun J, Sieper J. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002;20(Suppl 28):S34-7.
59. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34.
60. Baeten D, Van den Bosch F, Elewaut D, Stuer A, Veys EM, De Keyser F. Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol 1999;18:434-41.
61. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondyloarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44:186-95.
62. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys E, De Keyser F. Modulation of vascularity and expression of adhesion molecules by tnf alpha blockade in spondyloarthropathy: histologic and serologic evaluation in a placebo-controlled trial. Arthritis Rheum 2002;46(Suppl):S430.
63. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys E, De Keyser F. Differential effect of infliximab on the T and B cell synovial infiltration in spondyloarthropathy: histologic evaluation of peripheral arthritis in 15 patients. Arthritis Rheum 2002;46(Suppl):S430.
64. Gu J, Baeten D, Rihl M, De Keyser F, Van den Bosch F, Veys E, et al. Gene transcripts in the synovia of spondyloarthropathy (spondyloartropathie) are clustered into statistical subgroups, each with a unique potential in function, as well as in response to infliximab therapy. Arthritis Rheum 2002;46(Suppl):S435.
65. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.